Depomed’s License Agreement With Solvay Pharmaceuticals Clears HSR ... - Genetic Engineering News

by Pain management @ Tue, 13 Jan 2009 02:00:07 -0600
Depomed, Inc. ( NASDAQ:DEPO ) announced today that the previously announced product license agreement under which Solvay Pharmaceuticals will have exclusive rights for DM-1796 for the treatment of pain in the United States, Canada, Mexico and Puerto ...
  • Recent posts